Roche Group said on Wednesday that its sales stood at 15.1 billion Swiss francs in the third quarter of 2024, climbing 6% in Swiss francs and 9% at constant exchange rates from the same period a year earlier. Sales in the pharmaceuticals division grew 10% at constant exchange rates to 11.6 billion Swiss francs, while diagnostics division sales rose 6% at constant exchange rates year on year to 3.5 billion Swiss francs.
For the first nine months of 2024, Roche's sales were up 2% to 45 billion Swiss francs. The increase was 6% at constant currency rates.
"We made significant progress in our pharmaceuticals portfolio in the last quarter with five important regulatory approvals for our medicines, three positive phase III read-outs, and two acquisitions to strengthen our oncology and ophthalmology pipelines," CEO Thomas Schinecker stated, highlighting the US regulatory approval of cancer drug Itovebi.
